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a  b s  t r  a  c t
Objective: To assess the  cost-utility of the human papillomavirus (HPV) vaccination on the
prevention  of cervical cancer in the Brazilian Amazon region.
Methods: A  Markov cohort model was developed to simulate the natural evolution of HPV and
its progress to cervical cancer, considering the current preventive programs and treatment
costs.  The one-year transition probabilities were mainly based on empirical data of local
and  national studies. The model evaluated the  addition of the vaccine to three cervical
cancer-screening  scenarios (0,  3 or 10  exams throughout life).
Results:  The scenario of three Pap tests resulted in satisfactory calibration (base case).
The  addition of HPV  vaccination would reduce by 35% the incidence of cervical cancer
(70%  vaccination coverage). The incremental cost-effectiveness ratio was US$ 825 for each
quality-adjusted  life year gained. The sensitivity analysis conﬁrms the robustness of this
result,  and duration of immunity was the parameter with greater variation in incremental
cost-effectiveness ratio.
Conclusion: Vaccination has a  favorable proﬁle in terms of cost-utility, and its inclusion in the
immunization schedule would result in a substantial reduction in incidence and mortality
of  invasive cervical cancer in the Brazilian Amazon region.
©  2013  Elsevier Editora Ltda.
Custo-efetividade  da vacina  contra  o papilomavírus  humano  na região
Amazônica  brasileira
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Objetivo: Avaliar a  custo-efetividade da vacinac¸ão  contra o papilomavírus humano (HPV) na
prevenc¸ão  do câncer de colo  de útero na  região Amazônica brasileira.
Métodos:  Um modelo de coorte Markov foi desenvolvido para simular a  história natural do
HPV  e seu progresso para câncer de colo de útero, considerando os atuais programas de
 Study conducted at  the Universidade Federal de Rio Grande do  Sul, Porto Alegre, RS, Brazil, and at the Fundac¸ão de Medicina Tropical,
Manaus, AM, Brazil.
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prevenc¸ão  e os custos de tratamento. As probabilidades de um  ano de  transic¸ão foram
baseadas  principalmente em dados empíricos de estudos locais e nacionais. O modelo
avaliou a  adic¸ão  da vacina a  três cenários de  rastreio de câncer de colo de útero (0, 3 ou
10 exames ao longo da vida).
Resultados: O cenário de três exames de Papanicolau resultou em calibrac¸ão  satisfatória
(caso base). A  adic¸ão  de vacinac¸ão  contra o  HPV  reduziria em 35% a  incidência de câncer de
colo de útero (70% de cobertura de vacinac¸ão).  A razão incremental de custo-efetividade foi
US$ 825 para cada ano de vida ajustado para qualidade ganho. A  análise de sensibilidade
conﬁrma a robustez deste resultado, e a  durac¸ão  de imunidade foi o parâmetro com maior
variac¸ão na razão incremental de custo-efetividade.
Conclusão: A  vacinac¸ão  tem um perﬁl favorável em termos de  custo-utilidade, e sua inclusão
no calendário de imunizac¸ão  resultaria em reduc¸ão  substancial de incidência e de mortali-
dade relacionadas ao câncer de  colo de  útero na região Amazônica brasileira.
© 2013 Elsevier Editora Ltda. 
Introduction
The implementation of screening programs  for precursor
lesions has reduced mortality due to cervical cancer (CC) in
developed countries in recent decades; however, infrastruc-
ture  weaknesses and ﬁnancing difﬁculties for this strategy
have  limited CC control in developing countries.1,2
In Brazil, CC represents an important public health prob-
lem.  It is  estimated that 22,000 new cases of CC will be
diagnosed in  2013,3 corresponding to  an incidence rate of
17.5  cases per 100,000 women  and to a  mortality rate of 10.2
deaths  per 100,000 women.2 In the Brazilian Amazon region,
the  problem is  even more  serious. Due to a low screening
coverage for CC in the target population (less than 25%), a
high  incidence of the disease has been registered in that
area  (up to  46 cases/100,000 women), similar to  the inci-
dence rates in low-income countries, such as Uganda and
Mali.4
The ﬁnding that 70% of CC cases are caused by two
viral  serotypes motivated the establishment of preventive
strategies based on vaccination against HPV.5 Currently, two
vaccines  are available against HPV serotypes 16 and 18.6–8 Vac-
cines  are recommended for girls before they engage in sexual
intercourse, and they appear to have a  satisfactory effective-
ness.  The quadrivalent vaccine induces antibodies of high
efﬁcacy  against HPV and sustains stable levels for at least ﬁve
years,  in  addition to inducing robust immune memory,  sug-
gesting  that immunity is  enduring.9 Vaccine cross-immunity
has also been documented, with a  40% reduced incidence of
pre-malignant  cervical lesions induced by other oncogenic
HPV  serotypes (serotypes 31 and 45).10
Many  questions have been raised about the  role of vac-
cination  in CC preventive strategies, such as its clinical
effectiveness, target population, and duration of immunity,
but  the main concern addresses the economic implication
of  the vaccine. Unfortunately, the real effects of HPV vacci-
nation  on the incidence and mortality rates of CC won’t be
available  for decades. In the absence of longitudinal clinical
studies  that evaluate all of these variables, economic mod-
els  of analytical health decisions can be useful tools for the
evaluation of preventive strategies, by transporting data from
empirical studies into real-world simulations, allowing for
the  management of uncertainties and variations. Therefore,
cost-effectiveness analyses play a  key role in the evaluation
and  selection of strategies that should be implemented.
Until the present time, there have been limited data on the
clinical  and economic impacts of HPV vaccination in Brazil,
particularly  in the Amazon region, where screening programs
have  historically not been able to overcome geographical iso-
lation and signiﬁcant cultural barriers, as in the case of native
indigenous  populations. The present study aimed to conduct
a  cost-effectiveness and cost-utility analysis of HPV vaccina-
tion  in the Brazilian Amazon region, an  area with high CC
incidence.
Methods
Analytical  decision  model
A  Markov cohort model was  developed as a dynamic, closed,
and  deterministic decision analysis tool for the evaluation of
cost-effectiveness and cost-utility in preventive vaccination
(Fig. 1), using the TreeAge software (2009 version) (TreeAge
Software Inc. -  Williamstown, MA,  USA).
The analysis was performed from the provider’s perspec-
tive  (Brazilian Uniﬁed Health System). The target population
was  preteen girls (12 years of age), independent of previous
sexual  contact or HPV infection. The cohort time horizon
was  lifetime. The model simulated the natural course of HPV
infection  until its progression to  invasive cervical cancer, tak-
ing  into account the current prevention programs  (Pap test)
in  Brazil. For  each strategy (screening plus vaccination or
screening  only), the  model incorporated health state transi-
tion  probabilities, and the target population was  followed-up
from  adolescence until death in a  hypothetical cohort.
The  model incorporated the transition probabilities of
mutually  exclusive health states that refer to one-year cycles.
The model simulated the transition probabilities for 70 years
from  the age of vaccination (12 years of age). At each
transition, the model attributed the costs, quality of life,
and  death expectation according to the individual’s health
condition. The transition probabilities were based on empiri-
cal  data from the medical literature and referred to transitions
from  a  healthy state to a  possible HPV infection and low-
grade  squamous intraepithelial lesion (LSIL) induction, which
could  regress over time to normality, persist, or progress to
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Fig. 1 – Structure of the Markov decision model. The circle
above  represents the decision of whether or  not to
vaccinate.  The squares represent the states of health, and
the  arrows represent the transition probabilities. Each
individual  is followed-up from 12 years of age until death.
At  each one-year cycle, the individuals are at risk
of  developing precursor lesions, cancer, or  death.
high-grade squamous intraepithelial lesion (HSIL). This, in
turn,  could persist, regress to normality, or  progress to local-
ized,  regional, or metastatic invasive cancer (Fig. 1). Given the
development  of cancer, each individual could continue to  suf-
fer from the disease, evolve to death, or evolve to a  disease-free
state.  Each year, individuals would be  under an age-speciﬁc
risk  of death that is unrelated to  cancer. The odds of death
unrelated  to cancer are based on the life expectancy and mor-
tality  curves of Northern Brazil.11 The probability of death
unrelated to cancer was  calculated through the following for-
mula:
Probability  of death (age) =  1 − [survival probability (age + 1)/
survival  probability (age)]
Due to  the low coverage of typical preventive vaginal cyto-
logical  screening strategies of the Amazonian population, the
model  was  evaluated in three independent scenarios of vacci-
nation  or non-vaccination.4 The scenario with no cytological
screening throughout life (natural history of HPV infection)
was  compared with the scenarios for three and ten Pap
smear exams throughout a  woman’s life. At each screening
event,  cervical lesions would be found according to the crite-
ria  (Pap test sensitivity and speciﬁcity) described by national
studies. The detection of cervical lesions would require follow-
up  evaluations or treatment (colposcopy, cryosurgery, and/or
surgery),  for which they have been assigned a  likelihood of
success,  costs, and implications for the quality of life
of  the individuals of the cohort model. The economic analysis
adopted  a  5% annual discount rate for the cost and out-
come,  with the intent to convert future values into present
values.12
Model  parameters  and  presumption  of  base  case
The cohort’s transition probabilities from a  state of health to
another were established based on data from published stud-
ies.  Data from studies that evaluated epidemiology of CC in
the  Brazilian population were preferably used to calibrate the
model,  particularly when addressing the Brazilian Amazon
population. The supplementary data illustrate the values of
the  base case, variations of the sensitivity analysis, and the
data  source used in the model. The base case values represent
the  best estimate for each variable.
Where necessary, the model was calibrated by adjusting
the incidence of precursor lesions of CC to  adequately simu-
late  the  results of cancer incidence as  recorded in the Brazilian
Amazon  region.
Precursor  lesions
The likelihood of oncogenic HPV-induced precursor lesions
was  deﬁned in accordance with a  Brazilian study that assessed
the  incidence of squamous intraepithelial lesion in adoles-
cents  who were  followed up annually.13
For simpliﬁcation, LSIL was deﬁned as  grade I lesions,
and  HSIL was  deﬁned as  grade II and III lesions and in  situ
carcinoma. The age of sexual initiation was assumed to  be
13  years according to  a local epidemiological study,4 and the
incidence of LSIL peaked one year after the initiation of sexual
intercourse.
Due  to the paucity of epidemiological studies evaluat-
ing  progression probabilities and the regression of precursor
lesions,  this model used transition probabilities reported in
classic  international studies adjusted for one year (one cycle),
assuming  that the  mechanism of evolution of the disease is
universal.14,15 The probability of precursor lesion regression
to  normality was greater in younger women  (< 30 years) com-
pared  to those who were older than 30  years, reﬂecting more
persistent infections in older women.16
Cytological  screening  tests
The probability of detecting an asymptomatic cervical lesion
is  a function of the percentage of women who undergo Pap
smear  screening and the sensitivity and speciﬁcity of the test.
Incremental  evaluations of vaccinations of the population
were  performed for a  non-screening scenario and for scenar-
ios  in which individuals were screened three and ten times
throughout their lifetimes.
In  the scenario of three screening exams throughout an
individual’s lifetime, the individuals from the  model were  sub-
jected to the Pap test randomly within the second, fourth, and
sixth  decades of life. In the scenario of ten lifetime exams,
individuals were subjected to testing every ﬁve years from the
ages  of 25  to 40, and then every three years until the age of
55,  with a  ﬁnal exam at 65 years of age, in accordance with
a  Brazilian study that demonstrated that the frequency of
preventive  examinations tends to be higher between 40 and
59  years of age and decreases after 60 years of age.16
The sensitivity of the Pap test was  estimated at 70% for
LSIL  and 80% for HSIL. The speciﬁcity ranged from 80% to 90%,
according  to Brazilian studies.17–20
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The fundamental structure of the model is  based on clini-
cal  practice consistent with the clinical program procedures
advocated by VIVA MULHER, a program from the Brazilian
Ministry  of Health.21 Abnormal screening examinations were
forwarded to colposcopy, and tissues were  evaluated by biopsy.
If  HSIL was  histologically conﬁrmed, then the patient would
be  subjected to cryotherapy treatment or surgery. LSIL cases
underwent  new screening tests after six  months.
The costs related to each procedure were  derived from the
funds  allocation table of the Brazilian Ministry of Health.21,22
Invasive  cervical  cancer
Given the progression to cervical invasive cancer, the proba-
bilities  of its detection in  the  asymptomatic, early, regional, or
metastatic stages were  derived from a local epidemiological
study, as  were  the costs allocated to the initial treatment of
cancer.4 The tumor stages were  simpliﬁed as localized can-
cer (FIGO stage I and IIA), regional cancer (FIGO IIB to IVA), or
metastatic cancer (FIGO IVB). The standardized treatment was
surgery for localized cancer, chemotherapy combined with
radiotherapy for regional cancer, and palliative chemotherapy
for  metastatic cancer.4
The probabilities of death by cancer at each stage were
extracted from the global survival curves of longitudinal
studies.23 The ﬁve-year survival rate ranged from 92.0% for
localized  cancer to 55.7% for regional cancer and 16.5%
for  metastatic cancer. The annual incremental costs were  esti-
mated  at 10% of the initial value of the cancer treatment
and refer to screening examinations, control of sequelae, and
treatment-related toxicities or costs related to tumor recur-
rence.  Only direct costs that were assigned to cancer were
computed, and were  expressed in American dollars (US$).
Quality  of  life
Utility is a measure of the quality of life; it varies on a scale
from  0 to 1, where 0 represents death and 1  represents ideal
health.  The model multiplies the years of life by the utility
implicated in the health status to adjust survival by quality of
life;  the ﬁnal outcome of effectiveness is quality-adjusted life
years  (QALYs). The supplementary data illustrate these values.
The  completion of the Pap test implied a  slight decrease
in  the quality of life during the year of examination (0.99),
as  did colposcopy examinations and conization (0.95). Can-
cer  precursor lesions of the uterine cervix were considered
asymptomatic and caused no reduction in quality of life.
The  quality of life (utility) related to each tumor stage was
based  on an international study that speciﬁcally addressed
this  topic using a  validated analog scale, and ranged from 0.48
(metastatic  cancer) to 0.76 (localized cancer).24 The use of util-
ity  parameters from international studies as a  reference in the
present  model can be explained by the absence of Brazilian
studies  addressing this issue, but may  be supported by the
concept  of universality of human suffering.24
Vaccination  characteristics
The goal of this model is to evaluate the impact of the vaccine
on  the incidence of CC exclusively. It was  not developed to
distinguish  the effect of the bivalent from the  quadrivalent
vaccine. The reduction in the incidence of CC-inducing lesions
as a result of vaccination was  based on studies that originally
reported  the effectiveness of the vaccine.6–8
The vaccination coverage was  assumed at 90% of the target
population, based on the results of a  recently conducted vacci-
nation  campaigns against rubella in Brazil (in 2008 and 2011).25
In this nationwide vaccination strategy held in  a similar pop-
ulation,  the  a  95% coverage was achieved among females aged
between  12 and 19  years. Whereas HPV vaccine requires three
applications  (unlike rubella vaccine, which requires only one
dose),  the assumed coverage for this model was  slightly lower
(90%).
In  the base case of this model, it was determined that the
vaccine  provided immunity throughout life after three doses.
However,  there are major concerns regarding the duration of
immunity,  with signiﬁcant impact on the economic outcomes
of  vaccination. Simulations on the need for booster doses to
maintain  immunity (one to four doses throughout life) were
also  performed. Booster vaccination required only one dose;
therefore,  its cost was  estimated at a third of the initial vacci-
nation.
There  are no references for the price of the vaccine in  Brazil
for  the large-scale public sector, since the vaccine has not yet
been  incorporated into public health protocols. A  study con-
duct  by the Brazilian Ministry of Health estimated the price
of  vaccination at approximately US$ 180 (US$ 57 for each
dose  + US$ 9 as  cost of the applications).26 The Rotative Fund
(Pan-American Health Organization) for vaccine purchases
has  been a technical cooperation mechanism for the expan-
sion  of vaccination coverage.27 According to the Rotative Fund,
the  cost of the  vaccine dose to Brazil would be approximately
US$ 60 (US$ 17  for each dose + US$ 9 as cost of the appli-
cations). In the present model, the cost of initial vaccination
(three doses + implementation costs) for the base case was
estimated  at US$150.
However,  it was reported that the average price of vaccina-
tion  (three doses) in the American market is  US$ 360.28 For the
public  sector, the value negotiated by the Centers for Disease
Control and Prevention in the United States was US$  290.29
Measurement  of  outcomes
The results of the effectiveness were  shown as the num-
ber  of cancer cases prevented and deaths avoided, and the
utility  outcomes were shown as QALYs. The incremental cost-
effectiveness  ratio (ICER) was  calculated by the ratio of the
difference  in the cumulative total costs divided by the total
QALYs  obtained per woman that are attributed to the addition
of  vaccination to the existing screening program.  As a thresh-
old  for judgment, the international convention that a  strategy
can  be considered cost beneﬁcial if  the ICER is less than the
value  of GDP per capita (i.e., if  the additional cost of a  strategy
is  less than the value of GDP per capita to save a QALY) was
followed.30,31
Sensitivity  analysis
All economic assessments show a certain degree of
uncertainty, inaccuracy, or methodological controversy.12,31
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Table 1 – Health and economic outcomes for the addition of vaccination to the screening strategy (Pap test).
Preventive strategies Cost per  individual
(US$)
Quality-adjusted  life
years  (QALYs)
Incremental
cost  (US$)
QALYs saved
per individual
ICER (US$/QALY)
Non-screening scenario
Vaccination 270 24.8 -25 0.2 Dominant
No vaccination (natural course) 295 24.6
Scenario  of three screenings throughout the  lifetime (base  case)
Vaccination + screening 320 29.6 165 0.2 825
Only screening 155 29.4
Scenario  of ten screenings throughout the lifetime
Vaccination + screening 448 34.5 255 0.2 1,275
Only screening 193 34.3
Therefore, sensitivity analyses (one-way) were  performed for
variables with uncertainty over the base case values to assess
the  robustness of the  present study ﬁndings. These analy-
ses  recalculate the ICER considering the variations in a  given
parameter.
The  evaluated variables were cost of vaccination, effec-
tiveness of vaccination, scenario of the pre-existing screening
program,  vaccination coverage, time of immunity, annual dis-
count rate, and characteristics of the Pap test (sensitivity).
For  such analyses, the  variation values represent the authors’
judgment  regarding the uncertainty of the study parameter or
the variations in the results that have been published in the
medical  literature.
Results
Model  calibration
The primary outcome for the  calibration of the model was  the
incidence  of invasive cancer. In the scenario of the natural
course  of HPV infection, without screening exams, the model
simulated  a  4.2% lifetime risk of cancer, which equates to 34.1
invasive  CC cases per 100,000 women, considering the demo-
graphic  structure of the region studied.11 In the scenario with
screening  three times throughout an individual’s lifetime, the
risk  of cancer was  estimated at 3.4% (equivalent to 27.5 cases
per  100,000 women).
The  model was  well-calibrated to reported data of inci-
dence of CC in  the Brazilian Amazon. The prediction in  the
three-screenings scenario corresponded satisfactorily to
the  gross incidence rate of invasive CC as recorded in the
Brazilian  Amazon region in 2010 (28.2 cases per 100,000
women), and was  considered as  the baseline strategy to be
compared  with the addition of vaccination.4
Base  case  analysis
With a vaccination coverage rate of 90%, the vaccination strat-
egy  for preteen girls of the Brazilian Amazon region would
reduce  the lifelong incidence of CC by 42% in this population,
and  would reduce the mortality due to  CC by approximately
43.4%. The addition of the vaccine would generate an  incre-
mental  cost of approximately US$ 165 per woman  to the
current  strategy. The incremental cost-effectiveness ratio was
US$  825/QALY saved, given the base case parameters.
This assessment can be compared to the addition of the
vaccine  in other hypothetical scenarios of baseline cytological
screening in Table 1.
Fig.  2  compares the reduction in the incidence of CC for
the  various strategies (combination of cytological screening
and  vaccination), given the different vaccine coverage levels
simulated  by this model. It is noteworthy that the goal of a
50%  reduction in  CC incidence could be achieved by combin-
ing  high vaccination coverage (>  70%) with existing screening
procedures (> 3 Pap tests during lifetime).
Simulation  of  uncertainties
The sensitivity analyses reveal that vaccination tends to
provide  a  favorable proﬁle regarding cost-effectiveness,
despite changes in  the base case parameters proposed by the
sensitivity  analysis (Fig. 3).
The population vaccination coverage implies wide varia-
tions  in ICER, surpassing US$ 2,000/QALY for vaccine coverage
levels  of less than 50%. In a  vaccination coverage of 100%, the
ICER  would be  approximately US$ 500/QALY. The vaccination
strategy tends to dominate the cytological screening (3x) in
isolation,  i.e., it is less costly and more  effective (ICER ≤ 0)
for  vaccination costs lower than US$ 40 (all doses for primary
immunization). For vaccination costs above US$ 500, the vac-
cination  strategy requires approximately US$  2,200 to save one
QALY. A  vaccination effectiveness (reduction in the  incidence
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Fig. 2  – Effectiveness of strategies in the prevention of
cervical  cancer. Additional effect of vaccination in different
vaccine  coverage levels and preventive strategies.
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Fig. 3 – Sensitivity analysis. (A) Variation in vaccination coverage (30% to 100%); (B)  variation in vaccination cost (US$ 15
to US$ 500); (C) annual discount rate variation (0% to 10%); (D) variation in vaccine effectiveness in reducing the incidence
of pre-malignant lesions (25% to 70%); (E) variation in the number of lifetime booster shots (1-4 booster shots); (F) variation
in the sensitivity of the Pap test (50% to 90%).
of precursor lesions) of above 40%  maintains the  ICER below
US$1,000/QALY compared to the basal strategy. Increases in
the sensitivity of the Pap test tend to modestly increase the
ICER  of added vaccination by improving the efﬁciency of the
baseline  strategy, leading to a  relative reduction in  the addi-
tional  beneﬁt of the  vaccine.
If  revaccination is needed (at least one lifetime booster
dose) for the maintenance of immunity, the ICER would be
US$  1,650/QALY for the vaccination strategy, considering the
cost  of the vaccine booster at US$ 50 per dose. The need of
extra  doses substantially raises the costs of vaccine strat-
egy  without improving clinical effects, negatively altering
the  cost-effectiveness proﬁle of vaccination. In the case of
the  need for three booster doses, the  ICER would reach US$
3,200/QALY. The ICER would surpass US$ 4,000/QALY for the
hypothesis  of a  booster dose every 10 years (four booster doses
throughout  life).
The  parameter variation with the greatest impact in the
ICER  was  the annual discount rate. In an analysis without a
discount  rate, the ICER would be approximately US$ 30/QALY,
which  is  substantially less than a  discount rate of 10% (ICER =
US$ 4,500/QALY). These results are consistent with a  lifetime
horizon  cohort, as  proposed in the present study.
Discussion
Due to  increasing healthcare costs worldwide and the growing
constraints  arising from the scarcity of resources, healthcare
demands have increasingly sought to justify the incorpora-
tion  of a  new technique based on its cost-effectiveness or
cost-utility. To address this growing demand over the past
few  decades, methodological tools that promote rationality
in  decision-making in healthcare were proposed, aiming to
achieve  efﬁcient use of available resources.
The present study revealed that the addition of HPV vacci-
nation  to the  existing preventive strategy exhibits a  favorable
cost-effectiveness and cost-utility proﬁle in  the Brazilian Ama-
zon  region. Even when simulating a pessimistic vaccination
coverage rate (approximately 30%), the ICER of the  addition of
vaccination does not exceed the conventional limit of the GDP
value  per capita (about US$ 12,000 for Brazil in 2012) for any
other  uncertainty simulation. The ICER values resulting from
the  sensitivity analysis conﬁrms the favorable proﬁle of vacci-
nation  even if the limit value used were the GDP per capita in
the  Amazon region (US$ 6,350 per  capita). If the cost of vacci-
nation  is reduced to US$ 40 or less, with a vaccination coverage
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rate of 90%, then adding vaccination tends to dominate the
cytological screening strategy used alone.
Some authors have proposed a  different limit parameter
for  developing countries, suggesting that an  expense of one to
three times the value of GDP per capita for each QALY saved
would  represent a good use of resources in these countries.30
Although there is no consensus in Brazil regarding the limit for
a strategy to  be considered cost-effective, the  present study
conﬁrms  the favorable proﬁle of the addition of HPV vacci-
nation  in Brazilian regions with poor prevention programs
and  a  high incidence of CC according to the proposed crite-
ria.
To  better understand the implications of the HPV vac-
cine,  cost-effectiveness analyses published in countries facing
opposing  economic situations can be enlightening. Goldie
et  al. studied the cost-effectiveness of the HPV vaccine in
72  low-income countries, mostly countries in  Africa, which
are  characterized by high CC incidence rates.32 The analysis
showed  that the ICER of adding vaccinations in these countries
did  not surpass US$  200/QALY in 59 of the 72 countries, but had
a  major impact on the reductions in mortality and incidence
rates  of CC after the  vaccination of preteens. The analysis
also  showed the favorable cost-effectiveness proﬁle of the vac-
cine in regions where CC was  not controlled by conventional
screening programs.
Conversely, in  developed countries that succeeded in
controlling  CC incidence and CC-related mortality with
solid  gynecological screening programs, the HPV vaccine is
not  as  favorable from a  cost-effectiveness standpoint Ire-
land,  the United Kingdom, Switzerland, and Finland have
gross  incidence rates under 10 cervical cancer cases per
100,000  women. In these countries, cost-effectiveness stud-
ies  showed an additional cost of over US$ 20,000/QALY.33–36
In the United States, the ICER of adding vaccination exceeded
US$  43,000/QALY37. In the Netherlands, the CC incidence rate
is  less than six  cases per 100,000 women; however, the ICER
of  adding the HPV vaccine to the existing Dutch preventive
program  was  greater than US$ 70,000/QALY, classifying the
vaccination  strategy, according to  the authors, as non-cost-
effective.38
These evidences suggest that the greatest beneﬁt of the
vaccine  does not lie in its synergy with the basal population
screening programs, rather in their replacement in countries
or  regions whose programs  are insufﬁcient and poorly struc-
tured,  and have a high prevalence of oncogenic HPV infection.
Despite  the favorable economic proﬁle, the costs involved
in  the vaccination of preteen girls have caused widespread
concern, especially in developing countries. The HPV vaccine
(16  and 18) is one of the  most expensive vaccines on the
market, hindering its incorporation in  the healthcare systems
of  countries that would most beneﬁt from this technology.
According to the lesson learned from the vaccine against hep-
atitis B, which is now available for children in 89% of the
world’s  countries, including the poorest countries, only after
a  drastic reduction in  its price was  vaccination in global pro-
portions  possible.39
Although the cost of the vaccine is the main barrier
to its introduction in Latin America, other factors are also
important, such as  the feasibility of vaccinating the tar-
get  population, the competition with other vaccines, and its
acceptance.  The cultural acceptance of the vaccine has  not
been  evaluated in Brazil. It is worth noting that the general
public and health managers’ knowledge of HPV and its impli-
cations  are factors that strongly inﬂuence the acceptance of
the  vaccine by a population. Accordingly, strategies of commu-
nication  and education regarding the subject would be crucial
to  the success and effectiveness of any public health policy
for  the introduction of the HPV vaccine in Brazil, particularly
in  the Amazon region.
There  are limitations to the present study. First, due to lack
of  national data, some parameters have been calibrated based
on  international data. Second, the Markov assumption itself
establishes that transition probabilities depend exclusively on
the current health state, not on a  sequence of past health
states. Indeed, dynamic transmission models represent an
economic  evaluation methodology that uses probabilistic vari-
ations to more  reliably simulate the natural course of diseases
such  as CC, but requires large and robust epidemiological
data for its preparation (not commonly available). Finally, the
present  study considered only the effects of the vaccine on
the magnitude of CC, without considering the effects of the
vaccine  in reducing other types of cancer, such as  those of the
vulva,  vagina, anus, or head and neck, nor the beneﬁts of the
quadrivalent  vaccine on genital warts.
A recent study evaluated the cost-effectiveness of the
quadrivalent HPV vaccine in Brazil, using a  dynamic transmis-
sion  model to assess the effects on CC and genital warts.40
Kawai et  al. estimated that the ICER of vaccination strat-
egy  varied from US$ 448 to US$ 698/QALY when considering
only the bivalent vaccine (16 and 18) for control of the CC.
The  study also reported an even better outcome when con-
sidering  the effect of the quadrivalent vaccine to control
CC  and genital warts (US$ 219 to US$ 450/QALY). This data
suggest  that, if the additional beneﬁt of vaccine is  con-
sidered,  a more  favorable cost-effectiveness proﬁle may  be
achieved.
The  HPV vaccine may  also be effective in preventing
male cancers (such as  those of the penis and anus). Addi-
tionally, male vaccination may  improve the protection of
women  by reducing viral transmission. The cost-effectiveness
of  including Brazilian boys in HPV vaccination was  studied
by  Kim et  al.41 This strategy rendered a  small additional
gain in clinical beneﬁt (around 4% reduction in risk of HPV-
related  cancer), but a  high additional cost. The authors judged
vaccinating  boys as non-cost-effective and recommended that
efforts should be focused on expanding the coverage of girls
only.
The  high risk of invasive CC in the Brazilian Amazon region
implies an  urgent need to rethink the current preventive pol-
icy,  especially for underprivileged regions of the country. The
present  study was  the ﬁrst cost-effectiveness analysis of a
CC  preventive strategy directed toward a speciﬁc region of
the  country. The cost-effectiveness analysis of HPV vaccine
for  the Amazon region showed a  better proﬁle when com-
pared  to studies addressing this topic to Brazil as  a whole,
as  in the analysis published by Colantônio et al. (ICER = US$
10,181/QALY)42 and by Goldie et al. (ICER = US$ 9,600/QALY).43
Regarding public health, these results lead to the conclusion
that  public policies on women’s health, particularly on CC
prevention programs, should be decentralized (adjusted to
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regional reality) rather than uniform, given the heterogene-
ity  inherent in a  country of continental proportions, such as
Brazil.
Large-scale preteen vaccination in the Brazilian Amazon
region can be considered an investment in the future to
prevent,  in the coming decades, the premature deaths of
hundreds  of women  who have historically been neglected in
preventive government programs.
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Appendix  A.
Model parameters, costs, utilities, variation for the sensitivity
analysis, and respective sources
Variables Base case Variation§ Data source
(reference)
Properties of vaccination
Vaccination coverage – three doses (%) 90 30-100 25
Vaccination age (years) 12 4,13
Duration of immunity (years) lifetime 10-lifetime 9
Adherence to booster vaccination (%) 90 25
Preventive screening properties
Number  of tests during the lifetime (n) 3 0-10 4
Age screening started (years) 18 estimated
Sensitivity of Pap test (in LSIL scenario) (%) 70 50-90 17,18
Sensitivity of Pap test (in HSIL scenario) (%) 80 60-90 19,20
Speciﬁcity of Pap test (%) 90 17,18
Transition probabilities
Develop  LSIL after ﬁrst sexual intercourse 13
1st year 0.285 4,13
2nd year 0.117 4,13
3rd year 0.114 4,13
4th year 0.075 4,13
5th to 25th year (mean) 0.070 (± 0.022) 4,13
26th to 50th year (mean) 0.053 (± 0.012) 4,13
After 51st year (mean) 0.010 (± 0.008) 4,13
Reduction in the probabilities of developing LSIL
attributed to vaccination (%)
50 40-70 6,7,8
LSIL regression (<  30  years old) 0.193 14,  15, 16
LSIL regression (>  30  years old) 0.113 14,  15, 16
Develop HSIL from LSIL 0.110 14,  15
Develop invasive cancer from LSIL 0.00075 14,  15
Regression of HSIL 0.175 14,  15
Develop invasive cancer from HSIL 0.0078 14,  15
Invasive cervical cancer properties
Probability of localized cancer at diagnosis 0.315 4
Probability of regional cancer at diagnosis 0.488 4
Probability of metastatic cancer at diagnosis 0.197 4
Probability of death – localized 0.0165 23
Probability of death – regional 0.1101 23
Probability of death – metastatic 0.305 23
Precursor lesions treatment properties
Effectiveness of cryosurgery for LSIL (%) 85
Effectiveness of cryosurgery for HSIL (%) 75
Eligibility for cryosurgery (%) 85 estimated
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Appendix A  (Continued )
Variables Base case Variation§ Data source
(reference)
Others
Duration of cycle (years) 1 estimated
Age of sexual initiation (years) 13 4
Discount rate (%) 5 0-10 12,  31
Costs (US$)
Vaccination – three doses 150 15 -  500 26,  27,  28,  29
Booster shot 50 26,  27
Pap test 8 22
Medical appointment 5.5 22
Colposcopy 26.8 22
Cryosurgery 26.8 22
Conization 498 22
Hysterectomy type 1 1,236 22
Localized invasive cancer treatment 3,702 4
Regional invasive cancer treatment 8,420 4
Metastatic cancer treatment 2,625 4
Utilities
Normal population 1 estimated
Completion of Pap test (for 1 year) 0.99 estimated
Colposcopy and conization (for 1 year) 0.95 estimated
Localized invasive cancer 0.76 24
Regional invasive cancer 0.67 24
Invasive metastatic cancer 0.48 24
§  Range of  variation addressed in sensitivity analysis of  variables where lies any uncertainty. Costs expressed in American dollars (US$).
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